A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Clinical trial NCT05357950 · COMPLETED
Trial details
- NCT number
- NCT05357950
- Sponsor
- NeuroSense Therapeutics Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-31
- Primary completion
- 2023-11-02
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.